GlassScriptPhysician profile
Saghar Saber
NPI 1023405099
$1,257.65
in general payments reported to CMS, 2019-2025
14 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.53 · 2021: $358 · 2022: $364 · 2023: $214 · 2024: $116 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $522.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $706.61 | 2021-2024 | Biktarvy |
| Janssen Pharmaceuticals, INC | $117.42 | 2022 | |
| Exact Sciences Corporation | $70.73 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Organon LLC | $69.88 | 2021-2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $54.02 | 2022-2025 | |
| Alkermes, INC. | $45.84 | 2021-2024 | Vivitrol |
| Globus Medical, INC. | $35.68 | 2025 | Senza |
| Glaxosmithkline, LLC. | $33.55 | 2020-2023 | Shingrix, Arexvy |
| Redhill Biopharma INC. | $30.64 | 2025 | Talicia |
| Novo Nordisk INC | $24.87 | 2025 | Ozempic, Rybelsus |
| Phadia US INC. | $20.56 | 2024 | Immunocap |
| Sanofi Pasteur INC. | $18.43 | 2023 | |
| Merck Sharp & Dohme LLC | $15.61 | 2021 | |
| Lilly USA, LLC | $13.81 | 2025 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saghar Saber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.